Øystein Fløtten

1.8k total citations
33 papers, 1.1k citations indexed

About

Øystein Fløtten is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Øystein Fløtten has authored 33 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 8 papers in Epidemiology. Recurrent topics in Øystein Fløtten's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (16 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Øystein Fløtten is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (16 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Øystein Fløtten collaborates with scholars based in Norway, Denmark and Sweden. Øystein Fløtten's co-authors include Bjørn Henning Grønberg, Roy M. Bremnes, Stein Sundstrøm, Marit Slaaen, Ulf Aasebø, Nina Aass, Marianne Jensen Hjermstad, Vickie E. Baracos, Christian von Plessen and Tore Amundsen and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Infectious Diseases and The Lancet Oncology.

In The Last Decade

Øystein Fløtten

33 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Øystein Fløtten Norway	14	626	528	336	195	175	33	1.1k
François Chomy France	11	304 0.5×	251 0.5×	239 0.7×	217 1.1×	54 0.3×	29	727
Jeroen Mebis Belgium	19	448 0.7×	261 0.5×	112 0.3×	103 0.5×	119 0.7×	65	973
Trevor A. Jolly United States	14	460 0.7×	252 0.5×	314 0.9×	378 1.9×	56 0.3×	32	953
S. Klapper United States	5	561 0.9×	327 0.6×	387 1.2×	708 3.6×	59 0.3×	7	1.3k
Kosei Takagi Japan	15	527 0.8×	257 0.5×	276 0.8×	76 0.4×	147 0.8×	110	1.0k
J.M. Jonker Netherlands	6	187 0.3×	121 0.2×	236 0.7×	334 1.7×	42 0.2×	6	609
David E. Dawe Canada	15	212 0.3×	280 0.5×	101 0.3×	61 0.3×	132 0.8×	56	749
Geert‐Jan Creemers Netherlands	22	781 1.2×	329 0.6×	105 0.3×	67 0.3×	79 0.5×	65	1.2k
D A C Deans United Kingdom	13	257 0.4×	168 0.3×	380 1.1×	88 0.5×	38 0.2×	15	922
Lorenzo Dottorini Italy	13	330 0.5×	143 0.3×	167 0.5×	80 0.4×	90 0.5×	42	664

Countries citing papers authored by Øystein Fløtten

Since Specialization

Citations

This map shows the geographic impact of Øystein Fløtten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Øystein Fløtten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Øystein Fløtten more than expected).

Fields of papers citing papers by Øystein Fløtten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Øystein Fløtten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Øystein Fløtten. The network helps show where Øystein Fløtten may publish in the future.

Co-authorship network of co-authors of Øystein Fløtten

This figure shows the co-authorship network connecting the top 25 collaborators of Øystein Fløtten. A scholar is included among the top collaborators of Øystein Fløtten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Øystein Fløtten. Øystein Fløtten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grønberg, Bjørn Henning, Øystein Fløtten, Maria Moksnes Bjaanæs, et al.. (2025). High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial. Journal of Thoracic Oncology. 20(8). 1108–1119. 1 indexed citations

Kommedal, Øyvind, Tomas Eagan, Øystein Fløtten, et al.. (2024). Microbiological diagnosis of pleural infections: a comparative evaluation of a novel syndromic real-time PCR panel. Microbiology Spectrum. 12(6). e0351023–e0351023. 3 indexed citations

Eagan, Tomas, Øystein Fløtten, Kjersti Wik Larssen, et al.. (2023). Pleural Empyema Caused by Streptococcus intermedius and Fusobacterium nucleatum: A Distinct Entity of Pleural Infections. Clinical Infectious Diseases. 77(10). 1361–1371. 12 indexed citations

Fløtten, Øystein, et al.. (2023). “The challenge is the complexity” – A qualitative study about decision-making in advanced lung cancer treatment. Lung Cancer. 183. 107312–107312. 4 indexed citations

Halvorsen, Tarje Onsøien, Øystein Fløtten, Odd Terje Brustugun, et al.. (2022). Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer. Lung Cancer. 166. 49–57. 2 indexed citations

Grønberg, Bjørn Henning, et al.. (2022). Trajectory of health-related quality of life during the last year of life in patients with advanced non-small–cell lung cancer. Supportive Care in Cancer. 30(11). 9351–9358. 7 indexed citations

Grønberg, Bjørn Henning, Øystein Fløtten, Odd Terje Brustugun, et al.. (2021). High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. The Lancet Oncology. 22(3). 321–331. 76 indexed citations

Solheim, Tora S., et al.. (2018). Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: A pooled analysis of two randomized trials. Annals of Oncology. 29. viii609–viii609. 1 indexed citations

Grønberg, Bjørn Henning, Tore Wentzel‐Larsen, Vickie E. Baracos, et al.. (2018). A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer. European Journal of Clinical Nutrition. 73(7). 1069–1076. 26 indexed citations

10.

Grønberg, Bjørn Henning, Tore Wentzel‐Larsen, Vickie E. Baracos, et al.. (2016). Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clinical Nutrition. 35(6). 1386–1393. 112 indexed citations

11.

Halvorsen, Tarje Onsøien, Nina Jackson Levin, Roy M. Bremnes, et al.. (2016). Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer. Lung Cancer. 102. 9–14. 11 indexed citations

12.

Benth, Jūratė Šaltytė, Bjørn Henning Grønberg, Vickie E. Baracos, et al.. (2016). Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 18(2). e129–e136. 47 indexed citations

13.

Grønberg, Bjørn Henning, Jūratė Šaltytė Benth, Vickie E. Baracos, et al.. (2015). Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer. 90(1). 85–91. 71 indexed citations

14.

Grønberg, Bjørn Henning, Tarje Onsøien Halvorsen, Øystein Fløtten, et al.. (2015). Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncologica. 55(5). 591–597. 56 indexed citations

15.

Bremnes, Roy M., et al.. (2013). Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group. British Journal of Cancer. 109(6). 1467–1475. 50 indexed citations

16.

Grønberg, Bjørn Henning, Tudor–Eliade Ciuleanu, Øystein Fløtten, et al.. (2012). A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. Lung Cancer. 78(1). 63–69. 22 indexed citations

17.

Grønberg, Bjørn Henning, Stein Sundstrøm, Stein Kaasa, et al.. (2010). Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. European Journal of Cancer. 46(12). 2225–2234. 88 indexed citations

18.

Grønberg, Bjørn Henning, Roy M. Bremnes, Ulf Aasebø, et al.. (2008). A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer. 63(1). 88–93. 26 indexed citations

19.

Grønberg, Bjørn Henning, Roy M. Bremnes, Ulf Aasebø, et al.. (2007). A3-04: A phase III study by the Norwegian Lung Cancer Group: Pemetrexed + carboplatin vs. gemcitabine + carboplatin as first-line chemotherapy in stage IIIB/IV non-small cell lung cancer. Journal of Thoracic Oncology. 2(8). S317–S317. 2 indexed citations

20.

Grønberg, Bjørn Henning, Roy M. Bremnes, Ulf Aasebø, et al.. (2007). Pemetrexed + carboplatin versus gemcitabine + carboplatin in the treatment of stage IIIB/IV non-small cell lung cancer. Journal of Clinical Oncology. 25(18_suppl). 7517–7517. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact